$TOVX
Theriva Biologics, Inc.

2017 Q3 Form 10-Q Financial Statement

#000114420417055540 Filed on November 01, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.710M $2.100M
YoY Change -18.57% 31.25%
% of Gross Profit
Research & Development $4.137M $7.061M
YoY Change -41.41% -29.71%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K
YoY Change 0.0% 150.0%
% of Gross Profit
Operating Expenses $5.842M $9.156M
YoY Change -36.19% -21.41%
Operating Profit -$5.842M -$9.156M
YoY Change -36.19% -21.41%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$5.088M $667.0K
YoY Change -862.82% -83.9%
Pretax Income -$5.842M -$9.156M
YoY Change -36.19% -21.41%
Income Tax
% Of Pretax Income
Net Earnings -$10.93M -$8.489M
YoY Change 28.75% 13.08%
Net Earnings / Revenue
Basic Earnings Per Share -$4.90 -$0.09
Diluted Earnings Per Share -$4.90 -$0.09
COMMON SHARES
Basic Shares Outstanding 3.665M 91.44M shares
Diluted Shares Outstanding 3.665M 91.44M shares

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.05M $4.550M
YoY Change 362.64% -85.7%
Cash & Equivalents $21.05M $4.549M
Short-Term Investments
Other Short-Term Assets $1.260M $294.0K
YoY Change 328.57% -97.15%
Inventory
Prepaid Expenses $406.0K
Receivables
Other Receivables $612.0K
Total Short-Term Assets $22.31M $7.640M
YoY Change 192.02% -81.87%
LONG-TERM ASSETS
Property, Plant & Equipment $940.0K $580.0K
YoY Change 62.07% 20.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $30.00K
YoY Change -33.33% 200.0%
Total Long-Term Assets $970.0K $610.0K
YoY Change 59.02% 22.74%
TOTAL ASSETS
Total Short-Term Assets $22.31M $7.640M
Total Long-Term Assets $970.0K $610.0K
Total Assets $23.28M $8.250M
YoY Change 182.18% -80.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $4.240M
YoY Change -74.06% -29.64%
Accrued Expenses $3.680M $2.830M
YoY Change 30.04% 1059.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.53M $14.01M
YoY Change 25.12% -19.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $430.0K $210.0K
YoY Change 104.76% 5.0%
Total Long-Term Liabilities $430.0K $210.0K
YoY Change 104.76% 5.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.53M $14.01M
Total Long-Term Liabilities $430.0K $210.0K
Total Liabilities $16.08M $12.72M
YoY Change 26.42% -27.31%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.200M -$4.480M
YoY Change
Total Liabilities & Shareholders Equity $23.28M $8.250M
YoY Change 182.18% -80.65%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$10.93M -$8.489M
YoY Change 28.75% 13.08%
Depreciation, Depletion And Amortization $50.00K $50.00K
YoY Change 0.0% 150.0%
Cash From Operating Activities -$4.520M -$5.990M
YoY Change -24.54% -60.62%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$150.0K
YoY Change 33.33% -62.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$200.0K -$150.0K
YoY Change 33.33% -62.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.40M 640.0K
YoY Change 1837.5% -98.5%
NET CHANGE
Cash From Operating Activities -4.520M -5.990M
Cash From Investing Activities -200.0K -150.0K
Cash From Financing Activities 12.40M 640.0K
Net Change In Cash 7.680M -5.500M
YoY Change -239.64% -120.33%
FREE CASH FLOW
Cash From Operating Activities -$4.520M -$5.990M
Capital Expenditures -$200.0K -$150.0K
Free Cash Flow -$4.320M -$5.840M
YoY Change -26.03% -60.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2095000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7061000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9156000 USD
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
667000 USD
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-8489000 USD
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-136000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-8353000 USD
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-666000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5440000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15028000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-20468000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2164000 USD
us-gaap Net Income Loss
NetIncomeLoss
-18024000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2157000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6668000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22380000 USD
us-gaap Operating Expenses
OperatingExpenses
29048000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29048000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3681000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
36000 USD
us-gaap Net Income Loss
NetIncomeLoss
-24880000 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
us-gaap Share Based Compensation
ShareBasedCompensation
2906000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6428000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1193000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17517000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
199000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-199000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
814000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1447000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-16269000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20818000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4549000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1063000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-23000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2906000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1251000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-895000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16272000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
209000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-209000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
166000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18476000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
1995000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-557000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
19000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
111000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
172000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6358000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
633000 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1700000 USD
CY2017Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
200000 USD
CY2017Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
612000 USD
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 USD
CY2017Q3 us-gaap Prepaid Insurance
PrepaidInsurance
69000 USD
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
358000 USD
CY2017Q3 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
46000 USD
CY2016Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1677000 USD
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
406000 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
295000 USD
CY2017Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
130000 USD
CY2016Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
185000 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
358000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
186000 USD
CY2017Q3 syn Accrued Vendor Payments
AccruedVendorPayments
187000 USD
CY2016Q4 syn Accrued Vendor Payments
AccruedVendorPayments
400000 USD
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000 USD
CY2017Q3 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
806000 USD
CY2016Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
2211000 USD
CY2016Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
14000 USD
CY2017Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1265000 USD
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 USD
CY2017Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
341000 USD
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
261000 USD
CY2017Q3 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
0 USD
CY2016Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
52000 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1606000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
313000 USD
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3700000 USD
CY2017Q3 us-gaap Share Price
SharePrice
0.93
CY2016Q4 us-gaap Share Price
SharePrice
0.76
CY2016Q4 us-gaap Share Price
SharePrice
1.75
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.85 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0148 pure
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0141 pure
CY2016Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0139 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y9M18D
CY2016Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7908899 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
50000000 shares
CY2016 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
567257 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.58
CY2016 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
2.35
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17823000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24925000 USD
CY2017Q3 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17823000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24925000 USD
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128279674 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122950397 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128279674 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122950397 shares
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8353000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24880000 USD
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91441687 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91095990 shares
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8353000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24880000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91095990 shares
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2016Q3 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2017Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.885 pure
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117254196 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117172714 shares
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6901000 USD
CY2016Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6901000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
11952000 USD
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91441687 shares
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1091000 USD
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1301000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
128279674 shares
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91441687 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
122950397 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91095990 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128648365 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128566883 shares
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.02 pure

Files In Submission

Name View Source Status
0001144204-17-055540-index-headers.html Edgar Link pending
0001144204-17-055540-index.html Edgar Link pending
0001144204-17-055540.txt Edgar Link pending
0001144204-17-055540-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20170930.xml Edgar Link completed
syn-20170930.xsd Edgar Link pending
syn-20170930_cal.xml Edgar Link unprocessable
syn-20170930_def.xml Edgar Link unprocessable
syn-20170930_lab.xml Edgar Link unprocessable
syn-20170930_pre.xml Edgar Link unprocessable
tv477382_10q.htm Edgar Link pending
tv477382_ex31-1.htm Edgar Link pending
tv477382_ex31-2.htm Edgar Link pending
tv477382_ex32-1.htm Edgar Link pending
tv477382_ex32-2.htm Edgar Link pending